Processa Pharmaceuticals (PCSA) Q4 2024 earnings summary

Executive summary

• Clinical-stage biopharma focused on Next Generation Cancer (NGC) therapies, with two candidates in or through Phase 2 and one in preclinical development.

• Strategy targets modifying existing cancer drugs to improve efficacy and reduce toxicity, leveraging a proprietary Regulatory Science Approach aligned with FDA's Project Optimus initiative.

• Pipeline includes NGC-Cap (PCS6422 + capecitabine), NGC-Gem (PCS3117), NGC-Iri (PCS11T), and two non-oncology assets (PCS12852, PCS499) being considered for out-licensing.

• No product revenue to date; operations funded by equity offerings.

Financial highlights

• No revenue for 2024 or prior years; net loss of $11.85 million for 2024, up from $11.12 million in 2023.

• Research and development expenses rose to $7.27 million in 2024 (from $5.80 million in 2023), mainly due to Phase 1B and Phase 2 NGC-Cap trials.

• General and administrative expenses decreased to $4.78 million in 2024 (from $5.66 million in 2023), primarily due to lower professional fees and stock-based compensation.

• Cash and cash equivalents at year-end 2024 were $1.19 million; $4.5 million in net proceeds raised in January 2025 public offering.

• Accumulated deficit reached $87.2 million as of December 31, 2024.

Outlook and guidance

• Current cash and recent financing expected to fund operations into mid-2025; additional capital will be required to continue development programs.

• Plans to raise further funds through equity, debt, or strategic transactions; failure to secure funding may delay or halt development.

• Focus remains on advancing NGC-Cap Phase 2 trial and evaluating other pipeline assets.